Cargando…

High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis

BACKGROUND: There are limited data about the epidemiology and treatment-related outcomes associated with capreomycin resistance in patients with XDR-TB. Capreomycin achieves high serum concentrations relative to MIC but whether capreomycin has therapeutic benefit despite microbiological resistance r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pietersen, Elize, Peter, Jonny, Streicher, Elizabeth, Sirgel, Frik, Rockwood, Neesha, Mastrapa, Barbara, Te Riele, Julian, Davids, Malika, van Helden, Paul, Warren, Robin, Dheda, Keertan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409172/
https://www.ncbi.nlm.nih.gov/pubmed/25909847
http://dx.doi.org/10.1371/journal.pone.0123655
_version_ 1782368161844166656
author Pietersen, Elize
Peter, Jonny
Streicher, Elizabeth
Sirgel, Frik
Rockwood, Neesha
Mastrapa, Barbara
Te Riele, Julian
Davids, Malika
van Helden, Paul
Warren, Robin
Dheda, Keertan
author_facet Pietersen, Elize
Peter, Jonny
Streicher, Elizabeth
Sirgel, Frik
Rockwood, Neesha
Mastrapa, Barbara
Te Riele, Julian
Davids, Malika
van Helden, Paul
Warren, Robin
Dheda, Keertan
author_sort Pietersen, Elize
collection PubMed
description BACKGROUND: There are limited data about the epidemiology and treatment-related outcomes associated with capreomycin resistance in patients with XDR-TB. Capreomycin achieves high serum concentrations relative to MIC but whether capreomycin has therapeutic benefit despite microbiological resistance remains unclear. METHODS: We reviewed the susceptibility profiles and outcomes associated with capreomycin usage in patients diagnosed with XDR-TB between August 2002 and October 2012 in two provinces of South Africa. Patients whose isolates were genotypically tested for capreomycin resistance were included in the analysis. RESULTS: Of 178 XDR-TB patients 41% were HIV-infected. 87% (154/178) isolates contained a capreomycin resistance-conferring mutation [80% (143/178) rrs A1401G and 6% (11/178) were heteroresistant (containing both the rrs A1401G mutation and wild-type sequences)]. Previous MDR-TB treatment, prior usage of kanamycin, or strain type was not associated with capreomycin resistance. 92% (163/178) of XDR-TB patients were empirically treated with capreomycin. Capreomycin resistance decreased the odds of sputum culture conversion. In capreomycin sensitive and resistant persons combined weight at diagnosis was the only independent predictor for survival (p=<0.001). By contrast, HIV status and use of co-amoxicillin/clavulanic acid were independent predictors of mortality (p=<0.05). Capreomycin usage was not associated with survival or culture conversion when the analysis was restricted to those whose isolates were resistant to capreomycin. CONCLUSION: In South Africa the frequency of capreomycin conferring mutations was extremely high in XDR-TB isolates. In those with capreomycin resistance there appeared to be no therapeutic benefit of using capreomycin. These data inform susceptibility testing and the design of treatment regimens for XDR-TB in TB endemic settings.
format Online
Article
Text
id pubmed-4409172
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44091722015-05-12 High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis Pietersen, Elize Peter, Jonny Streicher, Elizabeth Sirgel, Frik Rockwood, Neesha Mastrapa, Barbara Te Riele, Julian Davids, Malika van Helden, Paul Warren, Robin Dheda, Keertan PLoS One Research Article BACKGROUND: There are limited data about the epidemiology and treatment-related outcomes associated with capreomycin resistance in patients with XDR-TB. Capreomycin achieves high serum concentrations relative to MIC but whether capreomycin has therapeutic benefit despite microbiological resistance remains unclear. METHODS: We reviewed the susceptibility profiles and outcomes associated with capreomycin usage in patients diagnosed with XDR-TB between August 2002 and October 2012 in two provinces of South Africa. Patients whose isolates were genotypically tested for capreomycin resistance were included in the analysis. RESULTS: Of 178 XDR-TB patients 41% were HIV-infected. 87% (154/178) isolates contained a capreomycin resistance-conferring mutation [80% (143/178) rrs A1401G and 6% (11/178) were heteroresistant (containing both the rrs A1401G mutation and wild-type sequences)]. Previous MDR-TB treatment, prior usage of kanamycin, or strain type was not associated with capreomycin resistance. 92% (163/178) of XDR-TB patients were empirically treated with capreomycin. Capreomycin resistance decreased the odds of sputum culture conversion. In capreomycin sensitive and resistant persons combined weight at diagnosis was the only independent predictor for survival (p=<0.001). By contrast, HIV status and use of co-amoxicillin/clavulanic acid were independent predictors of mortality (p=<0.05). Capreomycin usage was not associated with survival or culture conversion when the analysis was restricted to those whose isolates were resistant to capreomycin. CONCLUSION: In South Africa the frequency of capreomycin conferring mutations was extremely high in XDR-TB isolates. In those with capreomycin resistance there appeared to be no therapeutic benefit of using capreomycin. These data inform susceptibility testing and the design of treatment regimens for XDR-TB in TB endemic settings. Public Library of Science 2015-04-24 /pmc/articles/PMC4409172/ /pubmed/25909847 http://dx.doi.org/10.1371/journal.pone.0123655 Text en © 2015 Pietersen et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Pietersen, Elize
Peter, Jonny
Streicher, Elizabeth
Sirgel, Frik
Rockwood, Neesha
Mastrapa, Barbara
Te Riele, Julian
Davids, Malika
van Helden, Paul
Warren, Robin
Dheda, Keertan
High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title_full High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title_fullStr High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title_full_unstemmed High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title_short High Frequency of Resistance, Lack of Clinical Benefit, and Poor Outcomes in Capreomycin Treated South African Patients with Extensively Drug-Resistant Tuberculosis
title_sort high frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated south african patients with extensively drug-resistant tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409172/
https://www.ncbi.nlm.nih.gov/pubmed/25909847
http://dx.doi.org/10.1371/journal.pone.0123655
work_keys_str_mv AT pietersenelize highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT peterjonny highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT streicherelizabeth highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT sirgelfrik highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT rockwoodneesha highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT mastrapabarbara highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT terielejulian highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT davidsmalika highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT vanheldenpaul highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT warrenrobin highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis
AT dhedakeertan highfrequencyofresistancelackofclinicalbenefitandpooroutcomesincapreomycintreatedsouthafricanpatientswithextensivelydrugresistanttuberculosis